Transferred cold atmospheric plasma treatment on melanoma skin cancer cells with/without catalase enzyme in vitro

Yun Hsuan Chen; Jang Hsing Hsieh; I. Te Wang; Pei Ru Jheng; Yi Yen Yeh; Jyh Wei Lee; Nima Bolouki; Er Yuan Chuang

doi:10.3390/app11136181

Transferred cold atmospheric plasma treatment on melanoma skin cancer cells with/without catalase enzyme in vitro

Yun Hsuan Chen
, Jang Hsing Hsieh
, I. Te Wang
, Pei Ru Jheng
, Yi Yen Yeh
, Jyh Wei Lee
, Nima Bolouki
, Er Yuan Chuang

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Cold atmospheric plasma (CAP) is a promising tool to overcome certain cancerous and precancerous conditions in dermatology. A scheme of transferred CAP was first developed to treat melanoma (B16F10) skin cancer cells as well as non-malignant (L929) cells in vitro. CAP was transferred using a silicone tube with a jet system that was developed and was assessed as to whether it could generate reactive oxygen and nitrogen species (RONS) at near-room temperature. The transferred CAP was characterized electrically and spectroscopically. Biological data showed that the transferred CAP killed cancer cells but not non-malignant (L929) cells. Plasma treatment was effective with a time duration of 30 s, whereas non-malignant (L929) cells were less damaged during plasma treatment. In addition, catalase (CAT) enzyme was applied to neutralize and detoxify the RONS generated by the transferred CAP. These findings suggest that transferred CAP can be considered a melanoma cancer therapy.

Original language	English
Article number	6181
Journal	Applied Sciences (Switzerland)
Volume	11
Issue number	13
DOIs	https://doi.org/10.3390/app11136181
Publication status	Published - Jul 1 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Catalase
Cold atmospheric plasma (CAP)
Melanoma cell (B16F10)
Plasma cancer therapy
Reactive nitrogen species (RNS)
Reactive oxygen species (ROS)
Transferred cold atmospheric plasma

ASJC Scopus subject areas

General Materials Science
Instrumentation
General Engineering
Process Chemistry and Technology
Computer Science Applications
Fluid Flow and Transfer Processes

Access to Document

10.3390/app11136181

Cite this

@article{afd7d90e52c643bc8f3e758892a32b4b,

title = "Transferred cold atmospheric plasma treatment on melanoma skin cancer cells with/without catalase enzyme in vitro",

abstract = "Cold atmospheric plasma (CAP) is a promising tool to overcome certain cancerous and precancerous conditions in dermatology. A scheme of transferred CAP was first developed to treat melanoma (B16F10) skin cancer cells as well as non-malignant (L929) cells in vitro. CAP was transferred using a silicone tube with a jet system that was developed and was assessed as to whether it could generate reactive oxygen and nitrogen species (RONS) at near-room temperature. The transferred CAP was characterized electrically and spectroscopically. Biological data showed that the transferred CAP killed cancer cells but not non-malignant (L929) cells. Plasma treatment was effective with a time duration of 30 s, whereas non-malignant (L929) cells were less damaged during plasma treatment. In addition, catalase (CAT) enzyme was applied to neutralize and detoxify the RONS generated by the transferred CAP. These findings suggest that transferred CAP can be considered a melanoma cancer therapy.",

keywords = "Catalase, Cold atmospheric plasma (CAP), Melanoma cell (B16F10), Plasma cancer therapy, Reactive nitrogen species (RNS), Reactive oxygen species (ROS), Transferred cold atmospheric plasma",

author = "Chen, \{Yun Hsuan\} and Hsieh, \{Jang Hsing\} and Wang, \{I. Te\} and Jheng, \{Pei Ru\} and Yeh, \{Yi Yen\} and Lee, \{Jyh Wei\} and Nima Bolouki and Chuang, \{Er Yuan\}",

note = "Funding Information: Funding: This research work was financially supported by the Ministry of Science and Technology, Taiwan (MOST 108-2320-B-038-061-MY3 and 108-2221-E-038-017-MY3). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jul,

day = "1",

doi = "10.3390/app11136181",

language = "English",

volume = "11",

journal = "Applied Sciences (Switzerland)",

issn = "2076-3417",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

TY - JOUR

T1 - Transferred cold atmospheric plasma treatment on melanoma skin cancer cells with/without catalase enzyme in vitro

AU - Chen, Yun Hsuan

AU - Hsieh, Jang Hsing

AU - Wang, I. Te

AU - Jheng, Pei Ru

AU - Yeh, Yi Yen

AU - Lee, Jyh Wei

AU - Bolouki, Nima

AU - Chuang, Er Yuan

N1 - Funding Information: Funding: This research work was financially supported by the Ministry of Science and Technology, Taiwan (MOST 108-2320-B-038-061-MY3 and 108-2221-E-038-017-MY3). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Cold atmospheric plasma (CAP) is a promising tool to overcome certain cancerous and precancerous conditions in dermatology. A scheme of transferred CAP was first developed to treat melanoma (B16F10) skin cancer cells as well as non-malignant (L929) cells in vitro. CAP was transferred using a silicone tube with a jet system that was developed and was assessed as to whether it could generate reactive oxygen and nitrogen species (RONS) at near-room temperature. The transferred CAP was characterized electrically and spectroscopically. Biological data showed that the transferred CAP killed cancer cells but not non-malignant (L929) cells. Plasma treatment was effective with a time duration of 30 s, whereas non-malignant (L929) cells were less damaged during plasma treatment. In addition, catalase (CAT) enzyme was applied to neutralize and detoxify the RONS generated by the transferred CAP. These findings suggest that transferred CAP can be considered a melanoma cancer therapy.

AB - Cold atmospheric plasma (CAP) is a promising tool to overcome certain cancerous and precancerous conditions in dermatology. A scheme of transferred CAP was first developed to treat melanoma (B16F10) skin cancer cells as well as non-malignant (L929) cells in vitro. CAP was transferred using a silicone tube with a jet system that was developed and was assessed as to whether it could generate reactive oxygen and nitrogen species (RONS) at near-room temperature. The transferred CAP was characterized electrically and spectroscopically. Biological data showed that the transferred CAP killed cancer cells but not non-malignant (L929) cells. Plasma treatment was effective with a time duration of 30 s, whereas non-malignant (L929) cells were less damaged during plasma treatment. In addition, catalase (CAT) enzyme was applied to neutralize and detoxify the RONS generated by the transferred CAP. These findings suggest that transferred CAP can be considered a melanoma cancer therapy.

KW - Catalase

KW - Cold atmospheric plasma (CAP)

KW - Melanoma cell (B16F10)

KW - Plasma cancer therapy

KW - Reactive nitrogen species (RNS)

KW - Reactive oxygen species (ROS)

KW - Transferred cold atmospheric plasma

UR - https://www.scopus.com/pages/publications/85109984461

UR - https://www.scopus.com/pages/publications/85109984461#tab=citedBy

U2 - 10.3390/app11136181

DO - 10.3390/app11136181

M3 - Article

AN - SCOPUS:85109984461

SN - 2076-3417

VL - 11

JO - Applied Sciences (Switzerland)

JF - Applied Sciences (Switzerland)

IS - 13

M1 - 6181

ER -

Transferred cold atmospheric plasma treatment on melanoma skin cancer cells with/without catalase enzyme in vitro

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this